Multi-Asset Product Portfolio for Treatment of Various Cancers
Our proprietary phospholipid ether (PLE) platform technology features include the capacity to link to a wide variety of warheads, provide a significant increase in targeted oncologic warhead delivery and the ability to target all tumor cells. As a result, we're working to generate Phospholipid Drug Conjugates™ (PDCs) to treat a broad range of cancers with the potential to improve the therapeutic index of oncologic drug warheads, enhance or maintain efficacy while reducing adverse events by minimizing drug delivery to healthy cells, and increasing delivery to cancerous cells and cancer stem cells.
PDC Proprietary Product Pipeline
| PDC Program | Warhead/ Mechanism of Action |
Indication | Discovery | Pre-Ind | Phase 1 | Phase 2 | Collaboration |
|---|---|---|---|---|---|---|---|
| CLR 131 | Iodine-131 DNA Damage |
Multiple Myeloma |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
|
| B-Cell Lymphomas |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
|||
| Pediatric |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
 |
||
| Head & Neck |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
 |
||
| CLR 1900 | Proprietary Cell Cycle Arrest |
Solid Tumors |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Partnerships
| PDC Program | Warhead/ Mechanism of Action |
Indication | Discovery | Pre-Ind | Phase 1 | Phase 2 | Collaboration |
|---|---|---|---|---|---|---|---|
| CLR 2000 | Proprietary Cytoskeleton Disruption |
Performance-Based |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
| CLR 12120 | Solid Tumors |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
Proprietary Products
CLR 131
CLR 131 is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. The company’s lead PDC therapeutic, CLR 131, is currently in two clinical studies. The CLOVER-1 Phase 2 study in hematologic malignancies and the Phase 1 pediatric safety study. The CLOVER-1 study met the primary efficacy endpoints from the Part A dose-exploration portions conducted in r/r B-cell malignancies and remains under further evaluation in highly refractory multiple myeloma patients. A global, pivotal expansion cohort was launched in December 2020 in BTK inhibitor failed or suboptimal response Waldenstrom’s macroglobulinemia (WM) patients. The WM cohort will enroll up to 50 patients to evaluate the efficacy and safety of CLR 131 for marketing approval.
CLR 1900
CLR 1900 series is another internally developed proprietary PDC program leveraging a novel class of small molecule cytotoxic compounds as the warhead. The warhead functions by targeting a validated pathway that results in the inhibition of cell division and thereby killing the tumor cells. This series of molecules could produce a product candidate targeted to select solid tumors. Currently, the program is in early preclinical development.
Partnered Products
CLR 2000
CLR 2000 series is part of a collaborative PDC program with Avicenna Oncology, a leading developer of antibody drug conjugates (ADCs). The objective of the research collaboration is to design and develop a series of PDCs utilizing Avicenna Oncology’s proprietary cytotoxic warhead. Although Avicenna Oncology is a leading developer of ADCs, this collaboration was sought as a means to overcome many of the challenges associated with ADCs, including those associated with the targeting of specific cell surface epitopes.
CLR 12120
The CLR 12120 Series is a collaborative PDC program with Orano Med for the development of novel PDCs utilizing Orano Med’s unique alpha emitter, lead 212 conjugated to our phospholipid ether; the companies intend to evaluate the new PDCs in up to three oncology indications. Currently this series has shown efficacy in the first two animal models tested.